PHR Stock Overview
A biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Pharmena S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł5.98 |
| 52 Week High | zł9.18 |
| 52 Week Low | zł5.30 |
| Beta | 0.50 |
| 11 Month Change | -5.68% |
| 3 Month Change | 1.01% |
| 1 Year Change | -10.75% |
| 33 Year Change | -38.73% |
| 5 Year Change | -21.11% |
| Change since IPO | -78.25% |
Recent News & Updates
Shareholder Returns
| PHR | PL Personal Products | PL Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | 0.3% |
| 1Y | -10.7% | 16.8% | 15.8% |
Return vs Industry: PHR underperformed the Polish Personal Products industry which returned 12.5% over the past year.
Return vs Market: PHR underperformed the Polish Market which returned 14.3% over the past year.
Price Volatility
| PHR volatility | |
|---|---|
| PHR Average Weekly Movement | 3.7% |
| Personal Products Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 9.4% |
| 10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: PHR has not had significant price volatility in the past 3 months.
Volatility Over Time: PHR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 15 | Konrad Palka | www.pharmena.eu |
Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including face, hair, and body care products, as well as dietary supplement. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names.
Pharmena S.A. Fundamentals Summary
| PHR fundamental statistics | |
|---|---|
| Market cap | zł66.60m |
| Earnings (TTM) | zł28.19m |
| Revenue (TTM) | zł4.88m |
2.4x
P/E Ratio13.7x
P/S RatioIs PHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHR income statement (TTM) | |
|---|---|
| Revenue | zł4.88m |
| Cost of Revenue | zł1.63m |
| Gross Profit | zł3.25m |
| Other Expenses | -zł24.94m |
| Earnings | zł28.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | 2.53 |
| Gross Margin | 66.63% |
| Net Profit Margin | 578.26% |
| Debt/Equity Ratio | 0.03% |
How did PHR perform over the long term?
See historical performance and comparison